You can buy or sell PACB and other stocks, options, ETFs, and crypto commission-free!
Pacific Biosciences of California, Inc. engages in the development, manufacture and sale of an integrated platform for genetic analysis. Its products and services include PacBio sequel system, consumables, analytical software, and single molecule real-time (SMRT) compatible products. Read More It operates through the following geographical segments: North America, Europe, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.
Menlo Park, California
52 Week High
52 Week Low
Pacific Biosciences (PACB) Incurs Loss in Q1, Revenues Fall
Pacific Biosciences of California PACB incurred first-quarter 2019 adjusted loss of 20 cents per share, wider than the Zacks Consensus Estimate of a loss of 17 cents.
Seeking AlphaMay 3
Pacific Biosciences of California misses by $0.05, misses on revenue
Pacific Biosciences of California (NASDAQ:PACB): Q1 GAAP EPS of -$0.20 misses by $0.05. Revenue of $16.43M (-15.1% Y/Y) misses by $4.88M . Press Release...
Pacific Biosciences of California, Inc. Announces First Quarter 2019 Financial Results
MENLO PARK, Calif., May 03, 2019 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ:PACB) today announced financial results for its first quarter ended March 31, 2019, as attached. During the first quarter of 2019, the Company announced that it commenced its Early Access Program of the Sequel II System and the SMRT Cell 8M chip with five early access sites. All five early access sites successfully tested the new Sequel II System across a wide variety of customer samples with positive...
-$0.15 per share
-$0.20 per share